A study of a GLP-1 medicine, semaglutide, in people trying to quit smoking.
Recruiting now. Registry record last updated August 27, 2025.
- Who can join
- Adults 18 to 65, are trying to quit smoking, BMI 30+.
- What you take
- Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 4 years.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Tobacco Use.
Full scientific study title: Impact of Semaglutide on Tobacco Use and Related Health Behaviors.
Who can join
Adults 18 to 65, are trying to quit smoking, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Aged 18-65;
- report daily use of \>2 cigarettes per day (CPD), as this is a sufficient threshold for detecting tobacco use disorder, per MPI Oliver's published work57;
- meet criteria for obesity (BMI ≥30 kg/m2); and
- no immediate desire to quit tobacco use (using criteria form the clinical practice guidelines for treating tobacco dependence)
Key exclusion criteria
- Severe psychiatric disturbance precluding successful completion of the study, defined as
- personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome, and personal history of pancreatitis, type I or type II diabetes, diabetic retinopathy, or gastroparesis;
- current use of nicotine replacement therapy or other quit smoking medication;
- history of bariatric surgery;
- Current or past 6-month use of a GLP-1 agonist or any other weight-lowering/anti-obesity or glucose-lowering medications. These include (but are not limited to: sulfonylurea, insulin, metformin, thiazolidinediones (TZD), dipeptidyl peptidase-4 (DPP-IV) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, or GLP-1 analogs.
Where this trial is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Oklahoma1 site
- Health Promotion Research CenterOklahoma City, Oklahoma
Timeline
Started enrolling: July 1, 2024. Expected completion: June 30, 2028. Last updated on ClinicalTrials.gov: August 27, 2025.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
